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THE INHERITANCE OF HETEROGENEITY 
SARAH REGAN 
 
ABSTRACT 
Introduction: One important characteristic of solid tumors is heterogeneity at multiple 
levels of genetic and non-genetic organization. This can include gene mutations, 
epigenetic alterations, copy number changes, and chromosomal aberrations. Collectively, 
these alterations contribute as parts of a genome-defined system.  Thus, when genetic 
information is passed from mother to daughter cell in the context of cancer evolution, in 
contrast to normal cellular processes, an altered system inheritance is often transmitted. 
When the genome of a somatic cell is highly unstable, such as during certain 
phases of cancer initiation and progression, many novel alterations to the genome can be 
introduced in a short timeframe, effectively resulting in the macro-evolution of the 
somatic cell population (i.e., through the transition stages of cancer, including 
transformation, metastasis, and drug resistance). Unfortunately, these continually 
introduced, non-clonal alterations to the cell’s genetic information have often been 
described as background “noise” that does not function significantly in cancer. Rather, 
the driving force of cancer has largely been attributed to the accumulation of gene 
mutations in several key, driver genes. Despite the presumed significance of these driver 
genes by the gene mutation and clonal evolutionary theories of cancer, recent sequencing 
efforts have failed to identify common driver genes in the majority of cancer types. Based 
on this fact, and on the overwhelming presence of non-clonal alterations at multiple 
  vii 
levels of organization in the cells comprising tumors, the paradigm of cancer research 
requires re-examination. A better understanding of genome-level heterogeneity is 
necessary, as the genome, rather than individual genes, defines system boundaries and 
unifies the diverse individual molecular mechanisms of cancer through their contribution 
to major evolutionary transitions. 
Because inheritance is traditionally defined as a precise process of relaying bio-
information with extreme low frequencies of errors, it is challenging to explain how 
genetics work in cancer evolution.  It is thus timely to consider that potentially novel 
processes of inheritance occur in many types of cancer. The maintenance of a massive 
extent of multi-level heterogeneity in the cells of solid tumors over generations suggests 
that a less precise process is taking place. We have described this with a new term, “fuzzy 
inheritance,” wherein a range of variants, rather than specific variants (such as specific 
gene mutations or chromosomal aberrations), is recapitulated in the cell division process. 
This study aimed to elucidate the mechanism of fuzzy inheritance by examining the 
relationship between genome instability-linked karyotypic heterogeneity and growth 
heterogeneity, based on single-cell analysis of an in vitro cell culture model. By 
demonstrating that increased genome-level heterogeneity is reflected by increased and 
more variable levels of growth heterogeneity, it was hoped to establish that fuzzy 
inheritance correctly explains the maintenance of high levels of heterogeneity in these 
somatic cell populations. An example of this phenomenon was also studied in giant 
cancer cells, as they undergo division processes which appear to contribute to and 
facilitate genome instability. 
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Methods: To examine these concepts, various cellular profiling methods were 
used, including in-situ cell growth, cellular morphological comparison, and karyotype 
analysis. We first quantified the extent of variation in the growth rates of single cells; by 
selecting the fastest- and slowest-growing colonies from the parent population, and 
examining the extent to which growth heterogeneity was passed in subsequent 
generations of cells, the correlation between genome-level heterogeneity (as reflected by 
the karyotype) and growth heterogeneity was determined. We then examined an extreme 
example of fuzzy inheritance, wherein giant cancer cells containing massive amounts of 
DNA undergo extremely abnormal cell division events, yielding many normal-sized 
daughter cells with genomes significantly different from those of both the parent cell and 
other daughter cells. By studying the frequency and other aspects of these cells in two 
unequally stable cell lines, we sought to gain insight on one specific mechanism of fuzzy 
inheritance. 
Results: The data suggested that fuzzy inheritance can be demonstrated in 
multiple cell culture models. The extent and variability of karyotypic heterogeneity was 
reflected by those of growth heterogeneity, indicating the karyotype’s importance in 
facilitating cancer evolutionary processes.  Moreover, the cells with giant nuclei can 
generate diverse genome-level heterogeneity. 
Discussion: Because fuzzy inheritance allows for the less precise passage of bio-
information over generations in cancer cell populations, and for the effective introduction 
of numerous alterations to the genome in often brief spans of time, the cell population can 
constantly increase its evolutionary potential, which is essential for the major transition 
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steps of cancer evolution. The mechanism of fuzzy inheritance should be explored 
further, due to its clear importance in the processes underlying cancer initiation, 
progression, and drug resistance. 
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 1 
INTRODUCTION 
 
Cancer research is finally reaching a crucial point, where sufficient data have been 
obtained to critically evaluate the currently dominant cancer gene mutation theory and its 
clinical implications (Garraway & Lander, 2013; Heng, 2016; Vogelstein et al., 2013; 
Weinberg, 2014). A major concern in developing cancer therapeutics based on current 
theory is the decrease in efficacy of many drugs or treatment methods following the 
initial success of intervention. Part of this problem appears to be caused by the treatment 
itself, which may promote long-term drug resistance by increasing overall heterogeneity 
through the mechanism of genome chaos (Heng et al., 2010a; Horne et al., 2014). It is 
now clear that a precise process of inheritance in somatic cell populations (as in solid 
tumors), featuring the gradual accumulation of genetic mutations, is neither the primary 
mechanism of inheritance for most types of cancer, nor is it the dominant force driving 
cancer through its transition stages. Instead, the secret to the success of many types of 
cancer may lie in this aforementioned ability, to pass a range of variability in traits from 
cell to cell during cellular maintenance processes. Many would thus argue that the 
general mechanism of cancer is, by nature, evolutionary (Heng, 2007; Merlo et al., 2006; 
Podlaha et al., 2012). These concepts must be applied to the rationale underlying all 
cancer research, if we are to genuinely and extensively improve the methods by which 
cancer is diagnosed and treated. 
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Gene Isolations, Genome Sequencing, and Impacts on Cancer Research: Successes 
and Shortcomings 
 In the past fifty years, a great deal has been learned about genes, and how the 
information encoded in genes results in the functional components of our physiology. In 
particular, thanks to the technological advances that have come about with invention of 
whole-genome sequencing (WGS) and various –omics technologies, associations 
between numerous gene mutations and pathways and the types of cancers in which they 
occur  have been determined (Cheng et al., 2015; Heather & Chain, 2015; Li et al., 2014; 
Patel et al., 2013). Indeed, the Human Genome Project and the Cancer Genome Atlas 
project (TCGA) both demonstrated the incredible, multi-level complexity and inherent 
variability of our “manual to life,” the human genome (Collins & Barker, 2007; Wheeler 
& Wang, 2013). Despite the fact that these endeavors have yielded a truly massive 
amount of information, it cannot be overlooked that these projects were predicated on a 
conceptual framework which now appears to be far less reflective of the reality of human 
health and disease, as will be discussed further. Moreover, applying the knowledge 
gained from these large-scale efforts to clinical use has proven far more difficult than was 
previously expected (Li et al., 2014). The increased medical knowledge of cancer 
generally has not yet translated into any “game-changing” successes in improving cancer 
treatment methods, with the possible exception of the development of imatinib for 
chronic myelogenous leukemia (CML) (Jabbour et al., 2010). On the other hand, not only 
does the CML story represent an exception, but even in the case of CML, it has been 
demonstrated that imatinib is no longer an effective therapeutic agent once the blast crisis 
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stage has been reached (Horne et al., 2013). It is logical to ask, then, why there is still a 
gap between the ability to completely sequence the genome (and utilize similar –omics-
based technologies) and the ability to find predictable patterns to use as the basis of more 
effective and personalized treatment. To answer this question, the basic concept of cancer 
and common methodologies of cancer research must be considered. 
 
Gene Mutation Theory versus Multiple Levels of Genetic Heterogeneity: Can There Be 
Reconciliation? 
It was predicted at the start of the 21st century by leading research scientists that 
the next few years would see a revolution in our approach to cancer. In their seminal 
publication on the “hallmarks of cancer,” Weinberg and Hanahan (2000) described their 
expectation that a set of logical rules would become the guidelines to explain and 
simplify the “complexities of the disease” (p. 57). With these rules, they thought, cancer 
research would assuredly not proceed as it had been, merely elucidating ever more 
complex factors and relationships involved in the initiation and progression of cancer, but 
never yielding vast improvements in the effectiveness of diagnostic and treatment 
methods. The authors clearly recognized, as many had by then, that multiple, complex 
alterations to the genome are required for cancer to proceed (Boland, 2000; Callahan & 
Campbell, 1989; Fearon & Vogelstein, 1990; Porter-Jordan & Lippman, 1994). Ironically, 
however, their characterization of tumorigenesis as a multistep process comprised of the 
stepwise accumulation of key genetic mutations ultimately guided much of the effort in 
the subsequent fifteen years of cancer research away from finding the uniting, 
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simplifying factors in the mechanism of cancer.  
Two significant issues must now be addressed by the scientific community. The 
first, as genome sequencing has demonstrated, is that almost all solid tumors exhibit 
extensive heterogeneity at multiple levels of biological organization, including the gene, 
epigene, and genome levels (Bheda & Schneider, 2014; Fox et al., 2009; Heng, 2007; 
Huang, 2013; Wood et al., 2007). This is also true for tumors of a given cancer subtype 
with regard to their clinical presentation (Heppner, 1984; Welch, 2016). This observation 
is extremely important, because it stands in direct opposition to second issue: namely, the 
rationale of most gene mutation-centered research on tumorigenesis. This was described 
by Fox and colleagues (2009) as “cataloging all clonal mutations found in a variety of 
cancers in order to identify the key mutated genes of cancer” (p. 4948). The search for 
these key gene mutations, whether among patients with a specific subtype of cancer, 
among different tumors of the same patient, or even within a single tumor, has had far 
less success than was expected, and has instead demonstrated extensive heterogeneity in 
all these settings (Heng, 2007; Zardavas et al., 2015). This conflict brings into question 
the continuous efforts being made to identify common driver mutations (Hua et al., 2013; 
Huang, 2013; Vogelstein et al., 2013). 
To state it simply, the multiple levels of genetic/non-genetic heterogeneity that 
exist challenge the gene mutation theory of cancer, as now it is obvious that alterations at 
other levels, such as karyotype and epigenetic changes, are more important. This has led 
to the gradual realization the cancer problem needs to be treated as a somatic 
evolutionary issue, in which genome alteration (and not just gene mutation) plays a 
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dominant role. It should be pointed out that although the consideration of cancer as an 
evolutionary process is not really new, refocusing on the genome level rather than the 
gene level represents a new conceptual framework. In particular, the newly introduced 
genome theory of cancer evolution considers the karyotype (not individual genes) as 
defining the system inheritance or genetic blueprint, while genes only represent “parts 
inheritance” (Heng, 2009; 2016; Heng et al., 2011a). Indeed, the results of current cancer 
genome sequencing efforts have strengthened the theory’s validity. For example, the 
presence of massive karyotypic heterogeneity in most types of cancer indicates the 
necessity of studying genome alteration-mediated cancer evolution, because, as has been 
evidenced by a growing body of research, genome heterogeneity appears to be both the 
basis for macro-cellular evolutionary selection and the defining characteristic underlying 
the mechanism of cancer (Heng et al., 2013; Horne et al., 2015a). 
 
A Critical Review of Concepts Which Led to Current Theories of Cancer Development 
and Progression 
In order to account for what has prevented researchers in the past from more 
clearly understanding the mechanism of cancer (and what has thus slowed progress in 
improving diagnosis and treatment methods), several assumptions in current cancer 
theory should be briefly examined. In an attempt to gain insight on the processes 
underlying cancer, biologists looked to examples which had already been studied at 
length, wherein changes to genetic information occur over time; an obvious example, 
then, was organismal evolution. Darwin proposed the theory of natural selection in the 
 6 
19th century, suggesting that the evolutionary process is in fact facilitated by this 
mechanism in the biological world (Boero, 2015).  He argued that the fittest 
individuals/organisms, those that can best reproduce and yield fertile offspring, must 
necessarily succeed better than other individuals/organisms. It seems logical to conclude, 
then, that for these individuals/organisms with better fitness, the stepwise accumulation 
of heritable, small changes over time is quintessential. Refinements of Darwinian theory 
over time led to the concept of Neo-Darwinism, wherein an organism's full genetic 
complement is reflective of a gradual accumulation of gene mutations which resulted in 
adaptive phenotypes and ultimately the species’ evolution (King et al., 2007, “Neo-
Darwinism”); thus, scientists use this terminology to describe evolution generally. 
Indeed, an average medical dictionary will describe evolution using phrases such as, 
“...lineages accumulate successive genetic adaptations to the way of life that characterizes 
the species” (King et al., 2007, “Evolution”). 
 Clearly, the key assumption of gene mutation theory (i.e., that the accumulation of 
gene mutations over time leads to cancer) fits well with Neo-Darwinian evolutionary 
concepts. Why, then, has gene mutation theory failed to deliver so far? Is there any key 
difference between cancer evolution and organismal evolution? In fact, recent cancer 
genome sequencing efforts have suggested that for the majority of solid tumors, clonal 
evolution is difficult to identify (Heng et al., 2010a; 2010b; Heng, 2016). The very drastic 
gene/ genome alterations that occur during somatic cell evolution have also brought into 
question the currently accepted concept of inheritance. This issue of the “missing 
heritability” (Eichler et al., 2010; Heng, 2010) simply does not make sense when 
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compared to the principles of Neo-Darwinian evolution. However, because biological 
research has been heavily influenced by such principles for more than a century, cancer 
research has been focused on finding common patterns of gene mutations that seemed 
most likely to exist according to them.  
This focus began to appear promising and was ardently pursued following the 
discovery of the BCR-ABL fusion gene/ Philadelphia chromosome (Jabbour et al., 2010; 
Rowley, 1998), found to be present in a large proportion of CML cases. Significantly, this 
fusion gene also provided evidence in support of the theory of clonal evolution through 
the gradual accumulation of genetic mutations as a dominating force in cancer; this 
theory was first proposed by Peter Nowell in 1976 (Nowell, 1976). A quarter of a century 
later, the Hallmarks of Cancer model was presented, proposing that several acquired traits 
were required for cells to become malignant, and that these traits resulted from distinctive 
genetic mutations. It was thought that at least some of these mutations must be quite 
common among the cancer cells of most patients with a specific subtype of cancer, and if 
correctly identified, these could be used to revolutionize diagnosis and treatment methods 
(Hanahan & Weinberg, 2000). These commonly mutated genes were subsequently 
referred to as oncogenes and tumor suppressor genes, and support for the theory of their 
sequential mutation as a requirement for tumorigenesis (Hahn & Weinberg, 2002; 
Vogelstein & Kinzler, 2004) became widespread. 
More fuel was added to the fire for the gene mutation and clonal evolution 
theories of cancer with the discovery of several common gene mutations for a few 
different types of cancer, including colorectal cancer (as in p53 and RAS) and melanoma 
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(as in BRAF, NRAS, CDKN2A, and PTEN) (Davies et al., 2002; Fearon & Vogelstein, 
1990; Goel et al., 2006; Haluska & Hodi, 1998). However, despite the limited clinical 
success stories which have since supported these theories, the failure of large-scale 
sequencing projects including TCGA to demonstrate either common gene mutations 
which definitively cause cancer or patterns of gene mutations for most cancer types 
(Heng et al., 2013) further challenges the key assumptions behind these theories. Indeed, 
the massive diversity of gene mutations among and within clinical tumor samples that has 
been demonstrated by recent sequencing efforts (Heng et al., 2010a), the significance of 
this diversity in the process of cancer progression (Maley et al., 2006; Shibata, 2006), and 
the recently revealed existence of punctuated evolutionary phases in cancer progression, 
in which multiple novel genome-level alterations are introduced in a short amount of time 
(see below), suggest that the rationale of basing efforts to develop new therapeutic and 
diagnostic methods on gene mutation theory is far less justified than it was twenty years 
ago. To gain an improved and more clinically relevant understanding of the data that has 
been generated in the past two decades, a new conceptual framework is needed. 
 
New Framework, New Strategies: Hope for Radically Improving Our Understanding of 
the Mechanism of Cancer 
The scientific community’s best answer to the question of what precise 
mechanisms underlie cancer initiation and progression, which resulted from research 
based on the gene mutation theory, does not appear to reflect the reality of how most 
types of cancer arise and progress. This is because cancer is a disease of the genome, and 
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not of individual genes (Heng, 2016). This has become increasingly evident, particularly 
in light of the facts that: 1) there can be numerous gene mutations in even normal/healthy 
tissue (Biesterfeld et al., 1994; Duncan et al., 2010), and 2) more and more evidence has 
shown that there is simply not a limited, finite set of commonly shared, key cancer genes 
(Heng et al., 2010a; submitted). 
 Indeed, perhaps the question has been wrong from the outset, in that the 
mechanism, in fact, simply functions at a different level of genetic organization than that 
which has been given the most attention. Recently, a new concept was presented that may 
correctly answer this question. This concept is founded on several observations, the first 
of which is the aforementioned massive extent of heterogeneity present at multiple 
system levels in the cell populations comprising most solid tumors (Brock et al., 2009; 
Heng, 2007). This heterogeneity is not “noise,” but the driving force for cancer, which 
also explains why the common key cancer genes are hard to identify. The second is that 
the genome is the highest level of systematic organization of biological information 
within the cell, and individual genes contribute to cellular function only in this “genome 
context” (Heng et al., 2010a); this accounts for impacts on cell function and dynamics 
due to gene-, epigene- and genome-level alterations, as well as various forms of 
“environmental” impacts (Heng et al., submitted). (The relevance of this point is 
exceptional when compared to some of the basic principles of gene mutation theory, i.e.: 
mutant gene dictates production of mutant protein, which alters cellular function.) As 
such, the genome represents a key coding system.   The third observation is that somatic 
cell populations with unstable genomes, such as those in solid tumors, exhibit attributes 
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which collectively constitute evolutionary processes (Heng, 2007). Nearly all cancer gene 
stories can be linked to genome-level alterations (Heng et al., 2016; Vogelstein et al., 
2013), suggesting the dominant role of these previously ignored alterations in hidden 
mechanisms. This concept fits clinical observations well, in which almost all cancer 
display altered genomes (Heng et al., 2013). 
These new observations/ideas need to be integrated into the cancer evolutionary 
concept, and the genome theory of cancer evolution does so elegantly. 
 
The Genome Theory of Cancer Evolution: Part 1 – Introduction, Outliers, and 
Averages 
In addition to organismal evolution, defined by the gradual, stepwise 
accumulation of mutations over vast periods of time (Heng et al., 2010a), a great deal of 
evidence indicates that somatic cell evolution occurs in multiple physiological and 
pathological processes, including cancer, and quite likely also in hepatocyte and 
lymphocyte differentiation (Abdallah, submitted; Anatskaya & Vinogradov, 2010; Gentric 
et al., 2012). At its core, genome theory states that numerous genome-level alteration-
mediated changes to the cell’s bio-informational package, which are introduced at a very 
high frequency during multiple, distinctive periods of time in the course of cancer 
progression, act as the vehicle by which a cancer cell population can increase its adaptive 
potential and survive (Heng et al., 2010a; Horne et al., 2014). In particular, this 
mechanism promotes the success of a few outliers in the cell population, driving the 
process of somatic cell evolution (as the altered genomes of these outliers represent 
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increased genomic instability and an altered genome context/system inheritance), and 
promoting an increased survival advantage for tumor cells in lieu of having a more stable 
genome and better growth potential (Abdallah et al., 2013; Horne et al., 2014). This 
survival advantage is especially important in the face of increased environmental stress 
(during chemotherapy or radiation therapy, for example). Lastly, because of the 
significance of outliers in the somatic cell evolutionary process, averaging methods such 
as those used for data from high-throughput assays will be far less accurate in reflecting 
the reality of the genomic landscape of the tumor, which varies not only at multiple levels 
of system organization, but also over time (Abdallah et al., 2013; Heng et al., 2013); thus, 
even the most basic principle of the method by which tumors are analyzed is flawed in its 
application to this and other genome instability-mediated diseases or conditions. 
The genome theory of cancer evolution (Heng et al., 2009; Ye et al., 2007) offers 
insights which far more clearly explain and indicate the previously unrecognized 
significance of the massive heterogeneity characteristic of most types of cancer, and 
especially that of the complex, diverse chromosome aberrations therein. Moreover, this 
theory may provide the key to answering the question of how a certain extent of 
heterogeneity can be passed in somatic cell populations such as solid tumors.  
 
The Genome Theory of Cancer Evolution: Part 2 – Genome-Level Dynamics, the 
Punctuated Evolutionary Patterns in Cancer, and How Macro- and Micro-cellular 
Evolution are Related to These 
 If the passage of bio-information from mother to daughter cell constitutes genetic 
 12 
inheritance, then it must be considered that in the setting of somatic cell populations, this 
process is imprecise. During cell division, daughter cells inherit alterations at multiple 
levels (gene, epigene, genome) which occur much more frequently and consistently than 
would be predicted by what is traditionally considered the process of genetic inheritance 
(i.e. the highly precise passing of characters with low mutation frequencies) (Abdallah, 
submitted; Heng et al., 2009; Zegerman & Diffley, 2009). It is now clear that such clonal 
expansion is not the sole or dominant process in the tumorigenesis. As Henry Heng and 
colleagues explained (2010a), this process instead features, “…an involvement of 
multiple cycles of clonal and non-clonal expansion. Even during the typical clonal 
expansion phase, there are significant levels of heterogeneity within a cell population” (p. 
1074).  
As the genome is the highest level of system organization, genome-level changes 
(as reflected in the karyotype by clonal and non-clonal chromosomal aberrations, or 
CCAs and NCCAs, respectively) constitute an altered system inheritance (Abdallah, 
submitted; Heng et al., 2006; 2010a). This strongly suggests that the growth of solid 
tumors is, in fact, facilitated through the process of somatic cell evolution. There are 
several important ways in which somatic cell evolution differs from Neo-Darwinian/ 
eukaryotic organismal evolution. The most relevant to this discussion is that in the case of 
cellular evolution in solid tumors, two alternating phases occur, constituting cycles of 
stepwise, gradual micro-evolution (a process dominated by CCAs), and punctuated, 
discontinuous macro-evolution, in which NCCAs dominate (Heng et al., 2006; 2010a; 
2013) (Figure 1). In the punctuated phase, the genome is far more unstable than in cells in 
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the stepwise phase, and an extreme degree of heterogeneity is present.  Most importantly, 
during the punctuated macro-cellular phase of cancer evolution, the stress event-initiated 
contribution of multiple, aggressive outliers to growth and multi-level heterogeneity has 
been demonstrated to be a dominant, facilitating force in the mechanism of cancer 
evolution (Abdallah et al., 2013, 2014; Heng et al., 2009). What is facilitated, 
specifically, is the progression of cancer through its major transition steps. 
The significance of this concept cannot be overemphasized; cancer is an example 
of “evolution-in-action,” where this process can be witnessed occurring over years or 
decades rather than over millennia (as in organismal evolution). This helps explain the 
exceptional challenge facing cancer researchers and oncologists today, of aiming for a 
constantly “moving target” (Crews & Jamieson, 2013; Schwitalla, 2014; Zeijlemaker et 
al., 2014). Indeed, a major hurdle and definitive transition state in cancer progression is 
the development of resistance to treatment (Gatenby, 2009; Heng, 2007). This 
development appears to occur primarily as a result of the phases of punctuated macro-
evolution in cancer, and cyclically introduced, non-clonal, genome-level alterations act as 
the vehicle for this process. 
Additionally, the two phases of cancer evolution have been conceptually linked to 
the transition between macro- and micro-cellular evolution. Specifically, micro-cellular 
evolution is linked to gene/epigene alterations, while macro-cellular evolution is linked to 
karyotype-level alterations (Heng et al., 2010a; Heng, 2016). Although it was initially 
considered less acceptable to use the concept of punctuated evolutionary pattern to study 
cancer, as the Neo-Darwinian concept of cancer evolution is focused on the accumulation 
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of small genetic changes (i.e., gene and epigene alterations). At that time, it was 
challenging to explain the observed rapid and massive genome-level changes occurring in 
cancer cells. Now, with the progress of TCGA, punctuated macro-cellular cancer 
evolution has been well-demonstrated through the use of sequencing data (Baca et al., 
2013; Horne et al., 2015a; Klein, 2013; Navin et al., 2011; Wang et al., 2014). 
Figure 1. The phases of cancer evolution. Cancer evolution is a cyclic process comprised of alternating 
phases. The first of these consists of clonal, stepwise micro-evolution, wherein clonal chromosomal 
aberrations (CCAs) are passed relatively consistently from mother cells to daughter cells and are thus 
dominant. This “strategy” is taken up by the cell in amenable environmental conditions and offers a growth 
advantage, but as a trade-off, it also limits the adaptive potential of the cell population (i.e. a solid tumor). 
The second phase is the non-clonal, punctuated macro-evolutionary phase, defined by the presence of 
numerous non-clonal chromosomal aberrations (NCCAs). This increases the heterogeneity of the cell 
population and thus promotes increased adaptive potential of both individual cells and the tumor as a 
whole. The evolutionary process is primarily driven by the mechanism of NCCA formation, as this 
facilitates the passage of a greater or lesser extent of heterogeneity from generation to generation of cells. 
This translates to the ability of cells in a tumor to collectively move farther along the evolutionary path, 
through the major transition steps of cancer (i.e., immortalization, transformation, metastasis, drug 
resistance) (Abdallah et al., 2014; Heng et al., 2008, 2010a; Horne et al., 2014). Reproduced with 
permission from Abdallah et al., 2014 © Informa Healthcare USA, Inc. 
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The Genome Theory of Cancer Evolution: Part 3 – Genome Chaos 
One example of the dramatic impact that increased genomic instability can have 
on the genome context is observed in the phenomenon of genome chaos. An unstable 
genome, which by nature is highly dynamic, may undergo numerous, complex changes in 
a very brief span of time, resulting in “extreme structural and numerical alterations,” 
according to Liu and colleagues (2014, p. 528) (Figure 2). Genome chaos has been linked 
to cancer in both clinical and experimental settings, and can be used to describe a variety 
of large-scale, complex chromosomal rearrangements, including massive translocations 
and other types of alterations; some forms of it have been described with terms such as 
“chromoplexy” (i.e., translocations occurring at more than one location on multiple 
chromosomes) and “chromothripsis” (i.e., many rearrangements occurring within one or 
a few specific chromosomes) (Heng et al., 2006; 2011b; Liu et al., 2014; Meyerson & 
Pellman, 2011). Genome chaos can be triggered by various types of stress, including 
chemotherapeutic agents, and many different mechanisms can be used by the cell in 
response to these stresses which will result in chaotic genomes (Liu et al., 2014). This is 
particularly significant because it reiterates the concern of targeting a specific pathway in 
attempting to control or slow the process of cancer progression; when one pathway is 
hampered due to medical intervention, there are still many other pathways a cell can use, 
which may have unpredictable impacts on the patient’s condition (Heng et al., 2009). 
The alterations that are rapidly introduced into the chaotic genome at multiple 
levels of system organization are so numerous and extreme that their introduction, in fact, 
acts as the means by which the previously described process of macro-evolution can 
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occur during the punctuated phases of somatic cell evolution in cancer cell populations. 
This is possible because, while some cells will surely die because of their incomplete or 
dramatically altered genome package/system inheritance, some others will gain an 
increased potential to survive by random chance. At this point, surviving or “winning” 
cells will have the advantage, and serve to keep the cancer cell population from being 
eliminated completely. Through the survival and subsequent proliferation of these few, 
unique daughter cells of genomically chaotic cancer cells, somatic cell evolution can 
occur. 
Figure 2. Genome chaos as it occurs in sequence. Image A shows a standard example of a cell with 
normal karyotype. In image B, stress-induced fragmenting of the chromosomes occurs, also described as 
“C-Frag” or “chromosome shattering” (Liu et al., 2014; Stevens et al., 2011). If the cell survives this 
process, these newly cleaved segments of chromosomes will join to each other in different orientations 
compared their overall arrangement prior to the stress response, in part through the process of non-
homologous end joining, or NHEJ (C). Genome chaos is thus induced in the cell. A major effect of this 
process is an increase in genome-level heterogeneity (as well as in genetic and epigenetic heterogeneity). 
Following this dynamic process, selection events will occur such that some lucky cells (often, notably, 
those with karyotypes exhibiting less extensive chaos) will survive and proliferate in a clonal fashion (D). 
Reproduced with permission from Liu et al., 2014 © Landes Bioscience. 
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The Genome Theory of Cancer Evolution: Part 4 – Fuzzy Inheritance 
Having observed the massive extent of heterogeneity which is passed from 
mother cell to daughter cell during significant portions of tumor growth, it is now evident 
that a type of inheritance occurs in this process which does not reflect the central tenets of 
Neo-Darwinian evolution, which is based on Mendelian inheritance. Why is the 
maintenance of a certain level of genome-level heterogeneity, both spatially and 
temporally, helpful to cancer cell populations? A reasonable answer, based on the 
discussion above, is that maintaining an increased level of heterogeneity beyond that of 
the baseline in healthy somatic tissue improves the ability of cancer cells to adapt to a 
stressful environment, and thus more chances to survive. Our group has recently 
proposed a bold theory explaining these concepts, called “fuzzy inheritance” (Abdallah, 
submitted; Heng, 2016; Horne et al, 2015b). This is based on observations that in 
genomically unstable cell populations, the precise passage of specific gene mutations, 
epigenetic alterations, or chromosomal rearrangements occurs far less frequently than 
would be expected according to Mendelian inheritance; instead, what is passed on from 
mother to daughter cell is a given extent of genome-level heterogeneity. In other words, a 
mother cell passes a range of variants, rather than a fixed, specific variant. Through this 
mechanism, the cancer cell population will have a continually increasing adaptive 
potential; the majority of this increase will take place during the punctuated phases of 
cancer evolution, in which numerous NCCAs are introduced (Abdallah, submitted; Heng, 
2016; Heng et al., 2016). 
The evidence in support of this theory will be examined using several methods, as 
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discussed further below. 
 
The Genome Theory of Cancer Evolution: Part 5 – Genome Chaos Represents an 
Extreme Form of Fuzzy Inheritance at the Genome Level 
In review, because genome chaos produces a diverse array of new “blueprints” 
(altered systems of inheritance) in the daughter cells of dividing cells with chaotic 
genomes, a population of cells is produced featuring various different genomes, each with 
unique adaptive potential (Heng et al., 2016; Horne et al., 2015b). Chaotic genomes are 
observed more frequently in cells with increased genomic instability, such as polyploid 
giant cancer cells or PGCCs (Heng et al., 2016), and following the induction of genome 
chaos in these cells, abnormal cell division processes take place (Figure 3), leading to an 
uneven distribution of genetic materials. These cells have been studied at length by 
several groups (Walen, 2008; Zhang et al., 2014), and provide evidence in support of the 
concept that genome chaos serves as a means by which cancer cell populations can 
generate and maintain a massive extent of heterogeneity at the genome level (Heng et al., 
2016) (Figure 3). As was described, while the induction of such extreme genomic 
changes will result in the death of the majority of daughter cells, in this same gesture, 
evolutionary potential is pushed to the limit, and a few outliers will allow the cell 
population to persist. Understanding the relationship between levels of stress, genome 
chaos, how genome formation can be achieved through fuzzy inheritance, and the success 
of outliers at the expense of massive cell death is the key to understanding cancer 
evolution. 
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Figure 3. Examples of genome chaos and giant cells yielding various different daughter cells. A: An 
example of genome chaos observed in a Dox-treated MOSE cell. An individual, normal chromosome 
should have one unique, specific color. This image shows individual chromosomes that have undergone 
dramatic re-organization, so each chromosome features several colors, which demonstrates that multiple 
instances have occurred in which chromosomes were broken apart and then re-assembled in different 
orientations than those which were prior to the breakage events (Heng et al., 2013). These events have been 
referred to as “chromosome shattering and stitching” (Heng et al., 2016). Additionally, many chromosomes 
are far greater in length than normal. B, C, D: Each of these images, from observations of HT-29 human 
colon carcinoma cells cultured in situ, shows a group of smaller cells produced from one giant cell. Nuclei 
of normal size are visible surrounding the giant nucleus in Figure C. Note the dramatic difference in cell 
size between the giant cell and stochastically produced daughter cells; each of these cells will contain 
different amounts of DNA, and thus are representative of NCCAs once metaphase has begun (Heng et al., 
2016). Figure adapted from Heng et al., 2016. 
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Summary 
Because of the imprecision inherent to the process of somatic cell evolution in 
tumors, we propose that this newly identified mechanism, called fuzzy inheritance, serves 
as the mechanism of heterogeneity and the driving force behind cancer initiation and 
progression. In the setting of genomic instability, which is exacerbated by the high stress 
levels endured by cancer cell populations during drug treatment, having the greatest 
possible extent of fuzzy inheritance results in maximal adaptive potential; this potential 
would be severely limited if more precise mechanisms of inheritance were used. Far more 
logically than any arguments presented by gene mutation theory, fuzzy inheritance 
appears to explain how massive heterogeneity at multiple system levels is maintained and 
passed from generation to generation in genomically unstable somatic cell populations 
such as tumors. We hope to not only demonstrate the link between genome chaos and 
fuzzy inheritance through our examination of PGCCs, but also to characterize fuzzy 
inheritance through its impacts on growth heterogeneity. Finally, the correlation between 
growth heterogeneity and instability-mediated karyotypic heterogeneity will be 
examined, as this key feature of cancer cell populations served as the means by which 
insight was first gained on the mechanism of fuzzy inheritance (Abdallah et al., 2013; 
Heng et al., 2013). 
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OBJECTIVES 
 
Heterogeneity is the key to understanding cancer evolution. The search for the 
mechanism of heterogeneity has thus become a priority. In the course of this pursuit, we 
hope to explain the distinctive type of inheritance exhibited by successive generations of 
cancer cells in tumors; this “fuzzy inheritance” differs significantly from the traditional 
concept of inheritance. This project is focused on determining if the heterogeneity of the 
genome itself (as seen in the karyotype) and that of growth rates is passed differently 
among generations of unstable cells compared to this process in stable cells. With this 
strategy, we hoped to answer several pressing questions. For example, can a very stable 
genome inherit traits in a cumulative manner? More specifically, through which 
mechanisms is fuzzy inheritance itself passed at the genome level? 
To help answer these questions, the aims of this study are to: 
1) …provide additional evidence to illustrate the concept of fuzzy inheritance as 
the mechanism of somatic cell evolution in tumors by examining the genome 
heterogeneity and growth heterogeneity of single cells and cell populations of varying 
genomic stability. 
2) …examine heritable traits such as karyotype and growth rate among 
generations of somatic cell populations, in order to see if these reflect the maintenance of 
a certain level of heterogeneity according to the genomic stability of the population. 
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3) …study a specific example of the mechanism of fuzzy inheritance, wherein 
polyploid giant cancer cells stochastically produce a highly diverse population of 
daughter cells with maximal evolutionary potential. 
By examining the dynamic characteristics of cancer cell populations at multiple 
levels of system organization, this research will help improve scientific understanding of 
the complex nature of solid tumors. Elucidating which factors are most significant in 
proffering increased growth and adaptive potential to these malignancies can help 
advance the field of cancer research, particularly in the development of new diagnostic 
and therapeutic strategies. 
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METHODS 
 
I. Overview: 
Observations of cell division events in PGCCs (see introduction) were performed with 
the goal of establishing the validity of the theory of fuzzy inheritance, using two cell lines 
with different levels of genomic stability. Single cell analysis was also performed based 
on an in vitro cell culture model, to monitor both karyotypic and growth dynamics over 
time. By using cells from not only different cell lines, but also cells from earlier and later 
passages of the same line, a model was established featuring different levels of genomic 
stability, as this factor has been established in impacting genome heterogeneity, system 
dynamics, and cancer evolution (Stevens et al., 2013; Ye et al., 2009). With this model, it 
could be determined if greater genomic instability is correlated to increased NCCA 
frequency and increased karyotypic and growth heterogeneity (and therefore, increased 
adaptive potential). 
 
II. General Reagents/Methodologies: 
Cell Lines and Reagents: 
MDAH041 human fibroblasts (hereafter, “041 cells”) originated from a patient with Li 
Fraumeni syndrome, and feature only one functional copy of the TP53 gene. The cells 
used for experimentation were grown as part of a spontaneous immortalization model 
(Heng et al., 2006; Stevens et al., 2013). Brca1 conditionally inactivated mouse ovarian 
surface epithelium (MOSE) cells were derived from transgenic mice in the laboratory of 
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Dr. Barbara Vanderhyden at the University of Ottawa (Clarke-Knowles et al., 2007). 
These cells were kindly donated by Dr. Vanderhyden. A description of the primary culture 
isolation of these cells can be found in the cited text. HCT116 human colorectal cancer 
cells were kindly donated by Dr. Bert Vogelstein of Johns Hopkins Medical Institutions. 
HT-29 human colon carcinoma cells were purchased from ATCC. All cell lines were 
maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine 
serum, streptomycin (100 µg/ml) and penicillin (100 U/ml). 
 
Cell Culture: 
Cell culture plates and flasks were maintained in an incubator at 37°C with 5% CO2. 
Cells from all cell lines were maintained using standard cell culture procedures (“Animal 
Cell Culture Protocols and Applications,” n.d.). 
 
Cytogenetic slides preparation: 
Cytogenetic slides were prepared according to published protocol (Heng et al., 1993; 
2006; Padilla-Nash et al., 2007). Please see the cited texts for a detailed description of the 
slide preparation protocol. Briefly, a two-hour colcemid treatment was performed on cells 
grown to a confluence of 70%. A mitotic shake-off was then completed to procure mitotic 
cells; these cells were rinsed with PBS and briefly treated with a 0.4% KCl hypotonic 
solution at room temperature. Following treatment with hypotonic solution, cells were 
fixed for a total of three times in a solution of methanol and acetic acid, and the final of 
these fixative treatments was completed overnight at 4°C. Finally, cells were suspended 
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once more in 100 µL of the fixative solution, and placed onto glass slides. 
 
Spectral karyotyping (SKY): 
SKY was performed on metaphase slides according to published protocol (Heng et al., 
2006). Briefly, slides were treated with pepsin and fixed with formaldehyde. Denaturation 
and hybridization with either mouse or human denatured probes followed. SKY probes 
were purchased from Applied Spectral Imaging (“Applied Spectral Imaging,” 2015). 
Slides were washed and signals were distinguished. Chromosome karyotyping was 
completed based on color and size using software from the probe company. 
 
Karyotypic analysis and NCCA scoring:   
Each mitotic figure, of which 20-100 were analyzed for each cell line, was analyzed for 
numerical and structural aberrations. NCCAs were characterized as chromosome 
aberrations seen in the sample at a lower than 4% frequency or only in a single instance. 
CCAs were characterized by aberrations seen at a greater than 4% frequency and were 
only placed in this category if the given aberration was seen in both the parent cell 
population and in a subpopulation that arose from a single cell of the parent cell 
population. This strategy was based on published protocol and refined by Henry Heng 
and colleagues (Heng et al., 2006; Roschke et al., 2003). Karyographs were used to 
present all normal and abnormal chromosome structures. This allows for the visualization 
of heterogeneity at the genome level for a single cell. All chromosome structures are 
represented along the x-axis, and the frequency of each structure is indicated along the y-
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axis. 
 
Statistical analysis: 
For karyotypic data, heterogeneity was calculated by measuring all chromosome 
structures (including both normal structures and those with aberrations). A power analysis 
was performed to confirm statistically significant sample sizes. At α=0.95 and β=0.9, an 
appropriate sample size of 15 cells per sample was determined. Standard deviation was 
also compared against sample size to confirm appropriate consideration of variation. 
Variation lessened and began to remain consistent at a sample size of greater than 15 
cells. For NCCA analysis, 50-100 mitotic figures were used. For growth data (see 
description of experiments below), the number of cells in a colony, each of which arose 
from a single cell of the same cell line and passage, was quantified and compared for 
each cell in the sample. Growth rate heterogeneity was measured using the dimensionless 
value known as coefficient of variation (CV), or relative standard deviation, which is the 
average number of cells that arose from each originally tracked single cell, divided by the 
standard deviation of the data set. Statistically significant sample sizes of 15 cells were 
determined with the same power calculation that was used for karyotypic data analysis. 
At least 25 single cells were tracked during growth rate monitoring. 
  
 27 
III. Experimental Strategies: 
Experiment #1: Linking growth heterogeneity to genome-level heterogeneity using 
MDAH041 human fibroblasts 
-Hypothesis: It was hypothesized that heterogeneity can be passed over multiple 
generations in somatic cell populations, and that the consistency with which the degree of 
heterogeneity is passed is dependent on the stability of the genome. It was expected that 
cells with less stable genomes to pass an increased and more dynamic extent of 
heterogeneity over generations, manifested as a higher frequency and larger variety of 
NCCAs. On the other hand, for cells with more stable genomes, the extent of 
heterogeneity (i.e., frequency and variety of NCCAs) was expected to be passed in a 
more precise, clonal fashion, reflecting the greater genomic stability but lower adaptive 
potential of these cells. Through such a demonstration, the concept that fuzzy inheritance 
represents the mechanism of heterogeneity could be supported. Earlier passage 041 cells 
(passage 20) represented cells with less stable genomes, and populations of these cells 
were compared against cells from a later, more genomically stable passage of the same 
cell line (passage 54). In the course of the spontaneous immortalization of this cell line 
(Heng et al., 2006; Stevens et al., 2013), cells from passage 20 were observed to be in a 
punctuated evolutionary phase, exhibiting drastic changes to the karyotype and 
transcriptome from passage to passage. Cells from passage 54 and beyond, on the other 
hand, were observed to be in a stepwise evolutionary phase, exhibiting minimal changes 
to the karyotype and transcriptome over time. This model was established previously, and 
the relative genomic stability as described above was confirmed at that time (Heng et al., 
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2006). 
-Strategy: Using 041 cells, the growth of single cells was monitored, in situ, for nine days 
in gridded T-25 cell culture flasks. Grid squares measured 0.5cm x 0.5cm. Cells were 
plated at a concentration of 400 cells per flask. Following this, the fastest- and slowest-
growing sub-colonies were identified for isolation, and these colonies were isolated into 
separate T-25 flasks on day nine. Each isolation of a fast- and slow-growing sub-colony 
constituted a generation, and a total of five isolations were performed (yielding five 
generations of the fastest- and slowest-growing cells). Cell growth was monitored on a 
daily basis. In situ single cell counting was performed on day nine, and after one to two 
weeks of continuous culture, cells were harvested for chromosome analysis. Cell 
counting allowed for the examination of the extent of growth rate heterogeneity passed 
on through the generations, and for the determination of whether or not the consistency of 
this process occurred in accordance with the extent of genomic stability. For example, in 
a relatively stable cell line, it was expected that by selecting for the fastest-growing 
cells/colonies, observations of the following would occur: 1) a gradual increase in growth 
rates over generations, and 2) the maintenance over generations of a given extent of 
variation in the growth rates themselves. In contrast, it was expected that relatively 
unstable cells (such as 041 cells from passage 20) would exhibit considerable 
stochasticity from generation to generation in both genome-level and growth 
heterogeneity. The karyotypes of both passage 20 (041-p20) and passage 54 (041-p54) 
041 cells were examined, using spectral karyotyping (SKY), at Generation 1 and 
Generation 5 of experimentation. This allowed for not only the examination of changes to 
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the karyotype over time within each group (i.e., passage 20 cells at Generation 1 versus 
those at Generation 5), but also for comparison of the karyotypes of 041-p20 and 041-p54 
cells to each other at early and late time points in experimentation. Performing SKY 
analysis allowed for examination of the extent of karyotypic heterogeneity passed on 
through the generations (see above). Statistical analysis of growth rate patterns was 
performed on day nine to examine growth rate heterogeneity (see above). 
 
Experiment #2: Lateral comparison of single-generation heterogeneity within a given cell 
line and between different cell lines. 
-Hypothesis: Based on the hypothesis described above, the extent and variability of 
growth rate heterogeneity was compared between simultaneous “runs” of in situ single 
cell growth of the same cell type. Specifically, two to three simultaneous “runs” were 
compared to each other, using 041-p20 cells, and a similar comparison was performed 
using 041-p54 cells. It was expected that there would be less variability between 
measurements of growth rate heterogeneity in 041-p54 cells compared to those based on 
041-p20 cell growth, based on the increased genomic instability exhibited by the latter 
cell type (see description of Experiment #1 above). 
-Strategy: Three T-25 gridded flasks of 041-p20 cells were observed in parallel over nine 
days to compare the extent and variability of growth rate heterogeneity among different 
cell populations of 041-p20 cells. This protocol was also performed with 041-p54 cells 
with the same rationale. This allowed for a less temporally significant but still useful 
examination of genome instability in these different cell types. Statistical analysis of 
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growth rate patterns was performed on day nine to examine growth rate heterogeneity. 
 
Experiment #3: Validating results from Experiment # 1 using MOSE cells 
-Hypothesis: See hypothesis for Experiment #1. Based on this hypothesis, we aimed to 
ensure that the patterns of genome-level and growth heterogeneity described by fuzzy 
inheritance were observed in more than one cell line. For this reason, the extent and 
variability of heterogeneity of a genomically stable cell line (Brca1 conditionally 
inactivated MOSE cells) was examined over five generations of the fastest- and slowest-
growing cells. We based our determination of the genomic stability of the cells used in 
this experiment on the fact that these cells were generated clonally from a single cell; 
these clones were previously observed to be very stable (both in growth trends and 
karyotypically) compared to the original MOSE cell line from Vanderhyden lab. Because 
of the relative stability of this cell line, the extent of genomic heterogeneity (i.e., 
frequency and variety of NCCAs) and growth heterogeneity were expected to be passed 
in a more precise and consistent manner. 
-Strategy: The same strategy as in Experiment #1 was used. Unlike Experiment #1, in this 
experiment, in situ single cell counting and growth rate analyses were performed on day 
seven, due to the more vigorous growth of this cell line. To examine the relative stability 
of the genome of these cells over time, data of growth patterns and karyotypes were 
obtained and compared to a previous iteration of this experiment performed by Batoul 
Abdallah (Abdallah, submitted). 
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Experiment #4: Examining effects of genomic instability and genome chaos in polyploid 
giant cancer cells (PGCCs) 
-Hypothesis: Having established the link between growth heterogeneity and fuzzy 
inheritance, the next step was to search for the cellular mechanism of fuzzy inheritance. 
Based on recent observations, it was proposed that one mechanism of fuzzy inheritance 
can be generated by the abnormal, rapid cell division of a highly unstable cancer cell. It 
was previously discovered that in high-stress environments, cancer genomes can undergo 
the process of genome chaos (Liu et al., 2014). These chaotic cells can rapidly evolve 
into a new cell population with altered genomes. Thus, by directly monitoring these 
chaotic cells, their relationship with fuzzy inheritance can be demonstrated. In this case, 
HT-29 cells were used, as the genomic instability of this cell line results in an increased 
frequency of giant cell formation (Heng, unpublished observation). Observations of the 
chaotic genomes and abnormal cell division events that characterize these giant cells (see 
introduction), as well as the distinctly unique genomes of normal-sized daughter cells 
(compared with both the parent cell and each other), stand in strong support of the theory 
of fuzzy inheritance. 
-Strategy: In order to further characterize the impact of genomic instability on cell 
division events in giant cells and the subsequent survival and/or proliferation of 
abnormally generated (but normally sized) daughter cells, colonies of cells from two 
different cell lines (with different levels of genomic stability) were grown in situ on glass 
coverslips and examined using DAPI imaging. By using in situ culture and live imaging, 
the goal of demonstrating that these giant cells can undergo rapid division, generating 
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new cell populations with altered genomes could be achieved. Cells from the HCT116 
cell line were compared to HT-29 cells, as the former are more genomically stable than 
the latter. This information was based on previous SKY analyses by Heng lab and 
observations of the HT-29 cell line’s increased drug-resistant capabilities (Heng, 
unpublished observation). 
First, one hundred colonies from each cell line were examined, and the quantity of 
giant cells per colony was determined. This allowed us to re-affirm that giant cells form 
more frequently in cell populations with increased genomic instability. (Thus, it was 
expected that giant cells would be observed more frequently in colonies of HT-29 cells 
than in those of HCT116 cells.) Giant cells were defined as being more than four times 
the size of a normal cell. The presence was also noted of any big (but not giant) cells, 
which were defined as being two to four times the size of a normal cell. 
Next, the growth rates and other characteristics of the giant cells were examined 
in order to find answers to several questions. For example, when giant cells are observed, 
how often is there also evidence that abnormal cell division events have occurred, such as 
multiple, immediately adjacent, normal-sized daughter cells? Do giant cells only produce 
normal-sized cells, or are some of their daughter cells also larger than normal? Where do 
giant cells form in colonies, relative in space to the entire colony (i.e., on the periphery of 
the colony, or only centrally, or both)? Are they ever found in clusters, or only 
individually? Are more giant cells found relative to the age of the colony (i.e., is a large 
colony size needed for giant cells to form)? And importantly, in what configuration is the 
DNA of giant cells? Is the cell in interphase, or are chromosomes visible, and does this 
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have any correlation with the presence of abnormally generated daughter cells? Finally, 
though the answer to this question will require far more exploration in future studies, is 
there a sufficient or minimally necessary amount or type of genetic material/bio-
information that must be present to ensure the survival of a daughter cell produced by 
abnormal division of giant cells?  
By addressing these questions, it was hoped that insight would be gained on how 
giant cells both contribute to and reflect genomic instability, particularly when these cells 
divide unevenly (as this yields daughter cells with different amounts of genetic material 
encoding different information). It was hoped that to use these data could be used to more 
fully understand the imprecision of fuzzy inheritance and its impacts on cancer cell 
evolutionary processes.  
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RESULTS 
 
Experiment #1: Linking growth heterogeneity to genome-level heterogeneity using 
MDAH041 human fibroblasts 
Due to initial technical difficulties involving single cell culture, it was not 
possible for a direct examination to be performed on the consistency of how growth rate 
heterogeneity was passed over generations based on a single cell analysis of the in vitro 
cell culture model. Nevertheless, growth/cell division often occurred at significantly 
lower rates for the unstable cells of this model (i.e., the 041-p20 cells) compared to the 
stable cells (i.e., the 041-p54 cells). Cell death of the unstable cells also occurred 
frequently and consistently enough that quantitative data of growth rates was far more 
difficult to obtain than it was for the more stable cells. These observations support the 
previous conclusion that cell populations with unstable genomes display growth that is 
slower than average (Horne et al., 2015b). Because of these technical issues (i.e., slow 
growth provided fewer mitotic cells), spectral karyotyping was not completed for 041-
p20 cells to examine karyotypic heterogeneity.  
For 041-p54 cells, multi-color imaging was completed at the outset of these 
experiments to be used with SKY probes. However, as the camera used for SKY analyses 
is not currently functioning, SKY images were captured using a conventional imaging 
system with a fluorescent microscope. Clear evidence was demonstrated of the altered 
genome exhibited by cells from this passage. Indeed, despite the fact that marker 
chromosomes (with multiple translocations) were unchanged compared to the SKY 
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analysis done over twelve years ago (Figure 4, right panel), polyploidy was consistently 
observed in karyotypic images of the 041-p54 cells (Figure 4, left panel). The differences 
between the two images of Figure 4 also exemplify the karyotypic heterogeneity of this 
cell line, which is still present (though to a lesser extent) during more stable evolutionary 
phases. The coexistence of different subclones is quite interesting, and should be studied 
further. Technical issues also prevented the possibility of completing SKY analysis on 
041-p54 cells at the end of these experiments. 
 
Figure 4. Multi-color SKY imaging of 041-p54 cells. Multi-color imaging was 
completed on 041-p54 cells at the outset of Experiment #1. Polyploidy was consistently 
observed in karyotypic images of these cells (Regan, unpublished observation). 
 
Experiment #2: Lateral comparison of single-generation heterogeneity within a given cell 
line and between different cell lines. 
Following improvement of the culture conditions, the extent and variability of 
growth rate heterogeneity between simultaneous “runs” of in situ single cell growth was 
examined, both for 041-p54 and 041-p20 cells. Growth rate heterogeneity was quantified 
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and compared between three runs of Experiment A, for example, using the dimensionless 
value of coefficient of variation or CV (see Figure 5). This measure of the relative 
standard deviation of growth rates allowed for the determination of whether a greater and 
more variable extent of heterogeneity is characteristic of the growth of 041-p20 cells, 
compared to that of 041-p54 cells. As indicated in Figure 5, more variation was observed 
in the extent of growth rate heterogeneity between simultaneous runs of in situ growth for 
the less genomically stable 041-p20 cells, compared to when 041-p54 cells were used in 
the same experimental design. 
 
Figure 5. Variation between coefficients of variation (CV) of parallel trials of 041-p54 and 041-p20 
single cell tracking of growth rate heterogeneity. Measurements of growth rate heterogeneity, quantified 
as the relative standard deviation or CV, for multiple runs (either N=2 or N=3) in separate T-25 culture 
flasks of the same experiment. For example, in Experiment E, three simultaneous runs of in situ growth of 
041-p54 cells were monitored on a daily basis, culminating in the calculation of a CV for each run. This 
allowed for a comparison of variability in growth rate heterogeneity among different, simultaneously-
growing cells of the same cell line and passage. This also allowed us to determine whether 041-p20 cells 
have a tendency to exhibit a greater extent of growth rate heterogeneity overall, compared to the more 
genomically stable 041-p54 cells. 
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Experiment #3: Validating results from Experiment #1 using MOSE cells 
The growth rate heterogeneity of Brca1 conditionally inactivated MOSE cells was 
monitored over the course of five generations (see Methods). Cell growth was monitored 
on a daily basis (Figure 6). The growth rate heterogeneity of each generation was 
quantified using coefficient of variation, or CV (Table 1). This allowed for comparison of 
the relative standard deviation of growth rates for each generation (both between 
generations and between fast- and slow-growing cells of the same generation), and thus 
for examination of how consistently the extent of growth heterogeneity was passed. 
While growth rates of the fastest- and slowest-growing cells were expected to increase 
and decrease, respectively, over generations (Figure 7), patterns of growth rate 
heterogeneity were expected to remain relatively stable over generations. Two rounds of 
experiments were completed for the third, fourth, and fifth generations of cells. To 
examine how changes in growth rates themselves over generations compared with 
expectations (see Figure 7), the number of cells in each colony that arose from an 
individually tracked cell was determined (Figure 8, Figure 9). As Figures 8 and 9 portray, 
very different distribution patterns of growth (for both the fast and slow groups) were 
observed, compared to the expected patterns shown in Figure 7. 
 
Figure 6. Daily monitoring of colony growth from a single cell, in situ. This is an 
example of the initial identification of a single MOSE cell (on day 1, leftmost image). 
Daily growth monitoring followed this for seven days. 
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Figure 7. Expected growth trends of genomically stable cells over generations, based 
on selection for fast or slow growth. This is an illustration of expected changes in 
growth rate patterns from the first to second generations of cells. 
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Figure 8. Growth rates over generations following selection for the slowest-growing colonies. To 
examine trends in growth rates and growth rate heterogeneity of Brca1 conditionally inactivated MOSE 
cells, the number of cells in each colony that arose from an individually tracked cell was determined. 
Following selection for the slowest-growing colonies of Generation 1, the average number of cells per 
colony was expected to decrease over generations (see Figure 7), based on the aforementioned genomic 
stability of this cell line. 
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Figure 9. Growth rates over generations following selection for the fastest-growing colonies. To 
examine trends in growth rates and growth rate heterogeneity of Brca1 conditionally inactivated MOSE 
cells, the number of cells in each colony that arose from an individually tracked cell was determined. 
Following selection for the fastest-growing colonies of Generation 1, the average number of cells per 
colony was expected to increase over generations (see Figure 7), based on the aforementioned genomic 
stability of this cell line. 
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Table 1. Coefficients of variation (CV) of growth rates of the fastest- and slowest-
growing colonies of Brca1 conditionally inactivated MOSE cells. According to the 
theory of fuzzy inheritance, the relative genomic stability of a cell line is reflected by the 
consistency with which heritable traits are passed, such as growth rate heterogeneity. CV 
values are reported as percentages. 
 
 
To visually represent the growth rate heterogeneity (based on CV calculations) of 
these cells over generations, and the averages and outliers of these data, boxplots were 
generated (Figure 10). Boxplots in Figure 10 reflect data from Experiment #3. In Figure 
11, boxplots displaying similar data from a previous iteration of this experiment are 
shown. By comparing Figures 10 and 11, the relative stability of the cell line over a long 
period of time was examined as reflected by the similarity of trends in growth rate 
heterogeneity between the data from the current experiment and from its previous 
iteration. The new data of fast-growing colonies, shown in the right panel of Figure 10, 
confirmed the general trend of the accumulation of faster growth over generations. Also, 
comparing duplicates of the same generation in Generations 3, 4, and 5 provided useful 
insight for understanding variation in these data. Interestingly, less stability was observed 
in the growth rate trends of the slow-growing colonies, compared to what was expected 
 42 
(based on the results shown in Figure 11 from the previous iteration of this experiment 
and the previously established genomic stability of these cells). This will be addressed 
further in the Discussion section, but a possible explanation of this observation is that the 
overall growth of the cells in our experiment was much faster than that shown in 
Abdallah’s data. 
 
Figure 10. Growth rate heterogeneity of the slowest- and fastest-growing colonies 
over generations from Experiment #3. Data from Experiment #3 of growth rate 
heterogeneity over generations of Brca1 conditionally inactivated MOSE cells, based on 
selection of the fastest- and slowest-growing colonies. 
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Figure 11. Growth rate heterogeneity of the slowest- and fastest-growing colonies 
over generations from previous experimentation. Data (gathered prior to Experiment 
#3) of growth rate heterogeneity over generations of Brca1 conditionally inactivated 
MOSE cells, based on selection of the fastest- and slowest-growing colonies. Figure 
adapted from Abdallah, submitted. 
 
Experiment #4: Examining effects of genomic instability and genome chaos in polyploid 
giant cancer cells (PGCCs) 
Data of the frequency and characteristics of giant cells in two contrasting cell 
lines (HCT116 and HT-29) are detailed in Table 2. General observations and answers to 
specific questions prompted in the Methods section for Experiment #4 are addressed 
below. Images from observations are shown in Figures 13 and 14. 
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Table 2. Information from DAPI imaging of giant cells in colonies of HT-29 and HCT116 cells grown 
in situ. The frequency and characteristics of giant cells and the colonies in which they were observed were 
examined for two cell lines. As giant cells can serve as a vehicle for an extreme form of fuzzy inheritance, 
these data will be helpful for further study of the mechanism(s) of fuzzy inheritance. It is thus important to 
establish an index of the correlation between genomic instability and the presence/frequency of giant cell 
formation and division. 
 HT-29 HCT116 
General information   
Total number of colonies 
observed 
100 100 
Average number of cells in colony 
(standard deviation) 
163 (377) 124 (205) 
Colonies with at least one giant 
cell 
20 4 
Colonies with two or more giant 
cells 
6 0 
Colonies with at least one big cell 93 53 
Overall frequency of giant cells 20% 4% 
Giant cells observed…   
Total number 29 4 
Number observed to be located 
peripheral to colony 
20 4 
Number observed to be located 
central to colony 
9 0 
Giant cell frequency according to 
colony age* 
≥400 cells <400 cells ≥400 cells <400 
cells 
Number of colonies with giant 
cells 
7 13 1 3 
Number of colonies, total 9 91 6 64 
Frequency of giant cells 78% 14% 17% 3% 
Other observed phenomena and 
frequencies 
  
Uneven/non-bipolar cell division 
events, total 
32 7 
Massive polyploidy/ dramatic 
overabundance of 
chromosomes/chromatin 
8 3 
*Population doubling time of HT-29 cells is approximately 23 hours, according to 
ATCC. Population doubling time of HCT116 cells is approximately 21 hours, according 
to ATCC. 
 
Most significantly, data from scoring giant cells observed in situ in colonies from 
these two cell lines revealed a much higher frequency of giant cells in the HT-29 colonies 
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compared to the HCT116 colonies, which supported our expectations. Furthermore, more 
morphological heterogeneity and a higher frequency of abnormal cell division events 
were observed in HT-29 cells. These data support the concept of using giant cells to 
monitor cell line instability. 
Examination of the characteristics of giant cells and their immediate environs 
provided a wealth of information. Evidence of abnormal cell division events, including 
immediately adjacent, normal-sized daughter cells, was sometimes present where giant 
cells were observed, particularly in observations of HT-29 cells (see Figure 13E, G.) 
Generally, both normal-sized and big cells appeared to be produced by abnormal/ uneven 
division events of giant cells. Regarding the relative position of giant cell formation in 
colonies, giant cells were found more often at the periphery of colonies than centrally. 
Giant cells were occasionally found in clusters, and big cells were found in this formation 
more often. Interestingly, giant cells located centrally in the colony were never found in 
clusters (i.e., two or more), but giant cells at the periphery of the colony were sometimes 
found in clusters, as were peripherally-located big cells. Regarding giant cell frequency 
relative to the age of the colony, giant cells were more likely to be found in older/ larger 
colonies compared to smaller/ younger ones (see Table 2). 
Regarding the configuration of DNA in the cells’ nuclei, genetic material was 
observed to be present in giant cells in much greater quantity than normal. Fascinatingly, 
while it was usually observed that DNA in giant cells was present as loose chromatin 
(i.e., the cell was in interphase), the DNA of these cells was occasionally observed to be 
arranged into numerous, visible chromosomes (see Figure 13A, B, and F); this suggested 
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that the process of cell division was occurring, despite a massive excess of genetic 
material and thus a likely insufficiency of mitotic machinery. No clear correlation was 
present between chromatin status of giant cells and the presence of abnormally generated 
daughter cells. 
In considering differences in size between giant cells of the two different cell 
lines, giant cells were relatively equal in size. Occasionally, HT-29 giant cells were 
observed to be smaller than HCT116 giant cells. Generally, colonies of HT-29 cells 
tended to grow to slightly larger sizes on average, compared to colonies of HCT116 cells. 
(This could also be due to the faster population doubling rate of HT-29 cells; see Table 
2.) More variation in colony size was observed in colonies HT-29 cells compared to those 
of HCT116 cells, as shown in Figure 12. This aspect of HT-29 colony sizes recapitulates 
the increased genomic heterogeneity of HT-29 cells compared to HCT116 cells. 
One question remains standing: is there a sufficient or minimally necessary amount or 
type of genetic material/bio-information that must be present to ensure the survival of a 
daughter cell produced by abnormal division of giant cells? The answer to this question 
will be essential for more fully understanding the role of giant cells in passing an extreme 
form of fuzzy inheritance subsequent to their genome chaos-induced formation. 
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Figure 12. Colony size distribution for HT-29 cells and HCT116 cells. A greater range 
of variation in colony sizes was observed in cells from the more unstable of the two cell 
lines examined in Experiment #4.  
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Figure 13. Giant cells, massive polyploidy, and abnormal cell division events in HT-
29 cells. See page 49 for figure legend.  
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Figure 13. Giant cells, massive polyploidy, and abnormal cell division events in HT-29 cells. Images 
A-H each contain one or more examples of abnormal/uneven cell division events. Note the differently sized 
daughter cells of several of these events (see top right quarter of image D, top left quarter of image G). 
These adjacent daughter cells most likely have genomes that differ from each other and from that of the 
giant/parent cell. In Image C, strikingly abnormal cell division events are visible; note especially the 
example of a giant cell (encircled) that has recently divided into multiple, differently-sized (and most likely 
genomically unique) daughter cells. A similar, encircled example of a giant cell undergoing uneven 
division events is visible in Image E. On the right side of Image G, note the unique, meiosis-like division of 
a single cell occurring. Several different pathways related to the cell cycle are clearly being used by this 
highly heterogeneous population of HT-29 cells. Lastly, in Images A, B, and F, examples are shown of 
massive polyploidy and chromosome condensation in giant cells. The presence of chromosomes suggests 
that the process of cell division was occurring, despite a massive excess of genetic material and thus a 
likely insufficiency of mitotic machinery. 
 
 
Figure 14. Giant cells and abnormal cell division events in HCT116 cells. While giant 
cells and abnormal cell division events were observed less frequently in colonies of 
HCT116 cells grown in situ, compared to colonies of HT-29 cells, some examples of the 
former (left and right panels) and the latter (center panel) are shown. The observed 
relative infrequency of giant cells and uneven cell division events in colonies of HCT116 
cells supports the theory that genome instability is a required prerequisite to fuzzy 
inheritance. 
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DISCUSSION 
 
The aim at the outset of this study was to further characterize the mechanism of 
fuzzy inheritance, which facilitates the maintenance of a high degree of heterogeneity at 
multiple levels of system organization in individual somatic cells and cell populations 
(Abdallah, submitted; Horne et al, 2015b; Heng, 2016). While many have described this 
striking aspect of heterogeneity previously (Bloomfield et al., 2014; Brock et al., 2009; 
Heng et al., 2011b; Li et al., 2014), there have been limited efforts to explore its 
mechanistic aspects. As was discussed, genome-level alterations, and particularly 
NCCAs, now appear to have highly significant impacts on system behavior and dynamics 
in cancer cells (both individual cells and cell populations) over time (Heng et al., 2010a; 
2013); the fact that their role in cancer initiation and progression does not align with the 
expectations of most cancer biologists based on gene mutation theory (Heng et al., 2016) 
may explain why these types of alterations, and their impacts on genome-level 
heterogeneity, have not been closely examined in the majority of cancer studies. The 
focus of the current study on the mechanism of fuzzy inheritance, the relationship of this 
mechanism to genome instability and genome chaos, and how different heritable traits 
reflect this mechanism is part of a new push to further this lacking area of research. 
Growth heterogeneity is an important aspect of fuzzy inheritance, as it represents 
a heritable trait that is directly influenced at the level of the individual cell by the genome 
system status; if the cell features an altered genome, including multiple chromosomal 
aberrations (and especially if the numerous, dramatic alterations comprising genome 
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chaos are present), then the system inheritance is altered as well, which will be reflected 
by an increased and more variable extent of growth heterogeneity (Abdallah, submitted). 
As one of the most easily observed heritable traits, growth heterogeneity is an essential 
focus for elucidating the mechanism of fuzzy inheritance. A key finding of this study was 
that there appears to be a clear correlation between the level of genome stability in a cell 
population and how variable the extent of heterogeneity can be from generation to 
generation, or between each pair of mother and daughter cells. This supports evidence 
from previous studies of the impacts of genome instability on heterogeneity and how 
heritable traits are passed over generations in somatic cell populations (Abdallah, 
submitted). This correlation is evidenced especially by the results of Experiment #2, 
wherein greater variation in the extent of growth rate heterogeneity was observed 
between simultaneous runs of colony growth from cells that arose from the same, 
genomically unstable parent cell population, compared to variation seen in the more 
genomically stable cells of the experimental model. Interestingly, while there was some 
evidence of increased overall heterogeneity in the growth of the more unstable cells, the 
difference in this aspect between the unstable cells and the stable cells of this model was 
not as dramatic as was expected. However, the level of genome instability of 041-p20 
cells, which was previously established to be increased compared to the later-passage 
041-p54 cells (Heng et al., 2006; Stevens et al., 2013), seems to have resulted in more 
variable trends in growth among cell populations of the former group compared to the 
latter. In a clinical setting, notably, the difference in stability of the genomes of these 
groups of cells is a feature that would probably not be accounted for regarding 
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differential responses to stressors such as chemotherapeutic treatment. The fact that 
different cells in the same tumor may, in theory, all respond uniquely to such a stress (Li 
et al., 2014), is overwhelmingly important to the rationale behind this study. Another 
highly relevant point to consider is that being in culture can itself be a stress source for 
cells, especially if conditions are altered from ideal settings (Zhu et al., 2015). This may 
have contributed to the extent of growth heterogeneity and variability of this trait for the 
more stable cells used in this cell culture model, which was unexpectedly increased and 
closer to that of the unstable cells (see Figure 5). However, when this experiment was 
repeated multiple times, the unstable cell populations always displayed much higher 
uncertainty with higher variability. 
Further insight into the mechanism of fuzzy inheritance was gained from an 
opposing perspective by using a genomically stable cell line of Brca1 conditionally 
inactivated MOSE cells in Experiment #3. Some of the expected stability was seen in the 
extent of growth heterogeneity over generations of the fastest- and slowest-growing cells 
in this model (see Table 2). Fast-growing cells exhibited an increase in growth rate over 
generations, which supports our theory. Strangely, the slow-growing cells also exhibited 
increased growth rates over generations, though the fast growers had a more dramatic 
increase in growth rates than did slow growers. However, as was mentioned, it is possible 
that increased overall growth rates contributed to this unexpected result, which was 
especially surprising compared to Abdallah’s previous iteration of this experiment. 
United with Abdallah’s previous data, these results collectively stand in strong support of 
the theory of fuzzy inheritance. 
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Notably, given that this study was intended from the outset to address an 
extremely complex issue in cancer, wherein many different factors at multiple levels 
contribute to the overall result (i.e., the course of each individual case of cancer, 
including its initiation and progression), it is no surprise that the results reflect this 
extensive complexity and prompt further exploration of this research topic. This 
continued investigation is especially important because fuzzy inheritance is a novel 
concept in the field, and is potentially quintessential to vastly improving current scientific 
understanding of the general mechanism of cancer. 
A very promising finding of the study came from the examination of giant cells, 
which appear to act as vehicles by which an extreme form of fuzzy inheritance can occur 
in unstable cell populations. Morphological analyses of giant cells based on DAPI 
imaging decisively supported the concept that when cells exhibit massive polyploidy (and 
karyotypically-evident genome chaos) and undergo highly abnormal cell division 
processes, maximal fuzzy inheritance can occur. Additional live cell images supported 
this point, demonstrating that giant cells can produce many small cells at once, and most 
of these small cells display different karyotypes.  These findings need to be validated by 
further characterization of karyotypic alterations, transcriptome status, epigenetic 
changes, and gene mutations in both giant cells themselves and their daughter cells, in 
order  to gain a more complete picture of fuzzy inheritance and its impacts at all of these 
levels. However, along with the observation that increased frequencies of giant cells 
occur in cell lines with less genomic stability, the increased heterogeneity observed in the 
morphologies, colony sizes, and cell division processes of HT-29 cells also fits well with 
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the idea of using giant cells for monitoring cell line instability. This focus is especially 
promising because it is very new to the field of cancer research and appears quite logical; 
if further studies can quantitatively link giant cells to fuzzy inheritance and the extreme 
significance of karyotype alterations in cancer initiation and progression, then it might be 
possible to develop an index with which giant cells could be used as a quantitative, 
diagnostic marker, and/or a marker of stability, progression, or resistance. While 
pathologists have previously noted that giant cells are sometimes observed in tumor 
biopsy samples (H. Heng, personal communication, February 24, 2016; Osaka et al., 
2004), the assumption that these cells eventually die and do not actively contribute to the 
success of the tumor by producing aggressive daughter cells with highly altered genomes 
has led to disinterest in their potential significance. Based on our observations, future 
efforts in this laboratory will also focus on linking the presence of giant cells to drug 
resistance and evolutionary potential. 
A novel system is currently being developed which will eventually comprise a 
multi-level examination of alterations to the somatic cell genome; it is hoped that the 
laboratory's current work will contribute to the development a scoring system based on 
both quantitative and qualitative characteristics of cancer cell populations, at multiple 
levels of bio-information/ organization (i.e. gene mutations, epigenetic alterations, 
transcriptome alterations, chromosomal aberrations, and cell morphological 
characteristics). Thus far, the focus of this laboratory has primarily been on 
characterizing karyotypic alterations (especially NCCAs, based on their highly important 
role in cancer evolution) and changes in cell morphology (i.e., through examination and 
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scoring of giant cells, which are observed more frequently in cell populations with 
increased genetic instability).  
This research demonstrated that there indeed appears to be a gap in the 
understanding of inheritance in somatic cell populations, and that fuzzy inheritance 
logically and aptly explains how it is possible for very high levels of heterogeneity to be 
maintained over time in the cell populations comprising solid tumors. This mechanism 
serves as the physical means by which the inheritance of highly altered genome systems 
can occur. By passing a range of variants at multiple levels of system organization, rather 
than specific variants themselves (i.e., a specific gene mutation), fuzzy inheritance also 
constantly increases the evolutionary potential of the cell population. This concept should 
be explored more extensively, as it could vastly improve our current understanding of 
how drug resistance occurs. The work of this laboratory will help promote and further the 
study of genome-based heterogeneity and cancer evolution; as more and more evidence 
has demonstrated, this quality of many types of cancer is quintessential for both initiation 
and progression, and furthermore, serves as the foundation for the mechanism by which 
cancer evolution occurs. This topic is thus in urgent need of further research, both in 
studies of cancer and in those focusing on genetic instability-linked diseases or 
conditions.  
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